Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Verona Makes Strides With Niche Two-In-One COPD Treatment

This article was originally published in Scrip

Executive Summary

Verona Pharma's dual-acting novel therapy for chronic obstructive pulmonary disease (COPD) RPL554 has matched the bronchodilatory effects of salbutamol with fewer side-effects in a Phase IIa study, top-line data show.